In last trading session, KalVista Pharmaceuticals Inc (NASDAQ:KALV) saw 1.88 million shares changing hands with its beta currently measuring 0.02. Company’s recent per share price level of $16.01 trading at $0.22 or 1.39% at ring of the bell on the day assigns it a market valuation of $799.76M. That closing price of KALV’s stock is at a discount of -1.94% from its 52-week high price of $16.32 and is indicating a premium of 54.4% from its 52-week low price of $7.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.6 million shares which gives us an average trading volume of 1.07 million if we extend that period to 3-months.
For KalVista Pharmaceuticals Inc (KALV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.83 in the current quarter.
KalVista Pharmaceuticals Inc (NASDAQ:KALV) trade information
KalVista Pharmaceuticals Inc’s shares saw a change of 7.02% in year-to-date performance and have moved 3.22% in past 5-day. KalVista Pharmaceuticals Inc (NASDAQ:KALV) showed a performance of 22.78% in past 30-days. Number of shares sold short was 6.25 million shares which calculate 11.1 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 19.95% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -24.92% in reaching the projected high whereas dropping to the targeted low would mean a loss of -24.92% for stock’s current value.
And 5 analysts are in estimates of company making revenue of 1.16M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -17.63% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 8.75% while estimates for its earnings growth in next 5 years are of 56.58%.
KalVista Pharmaceuticals Inc (NASDAQ:KALV)’s Major holders
Insiders are in possession of 1.47% of company’s total shares while institution are holding 112.39 percent of that, with stock having share float percentage of 114.06%. Investors also watch the number of corporate investors in a company very closely, which is 112.39% institutions for KalVista Pharmaceuticals Inc that are currently holding shares of the company. VR ADVISER, LLC is the top institutional holder at KALV for having 6.25 million shares of worth $73.62 million. And as of 2024-06-30, it was holding 13.5179 of the company’s outstanding shares.
The second largest institutional holder is TANG CAPITAL MANAGEMENT LLC, which was holding about 4.22 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.1252 of outstanding shares, having a total worth of $49.7 million.
On the other hand, SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 3.18 shares of worth $50.87 million or 6.36% of the total outstanding shares. The later fund manager was in possession of 1.4 shares on Mar 31, 2025 , making its stake of worth around $22.39 million in the company or a holder of 2.80% of company’s stock.
